Need help finding what you are looking for?
Contact Us
PUBLISHER: FirstWord Group | PRODUCT CODE: 1355799
PUBLISHER: FirstWord Group | PRODUCT CODE: 1355799
Ulcerative Colitis - KOL Insight
PUBLISHED: annual subscription
PAGES:
DELIVERY TIME:
SELECT AN OPTION
KOLs generally welcome the approval of Eli Lilly's IL-23 inhibitor Omvoh but without significant advantages over established anti IL-23 therapies how can Eli Lilly break into this crowded market? Bristol Myers Squibb is finding it tough going to build support and use of its S1P modulator Zeposia - KOLs explore what lies beneath its sluggish performance. KOLs critically assess the prospects of launched and pipeline therapies.
In addition to the full report, licensed users have access to the following KOL Bulletins via the Attachments area.
Table of Contents
Executive Summary (11)
Future treatment algorithm
Research objectives (202)
- Marketed drugs (146)
- TNF inhibitors (29)
- Entyvio (vedolizumab; Takeda) (21)
- Xeljanz (tofacitinib, CP-690,550; Pfizer) (19)
- Stelara (ustekinumab; Janssen) (11)
- Zeposia (ozanimod; Bristol Myers Squibb) (18)
- Jyseleca (filgotinib; Galapagos/Gilead Sciences) (10)
- Rinvoq (upadacitinib; AbbVie) (18)
- Omvoh (mirikizumab (Eli Lilly) (20)
- Pipeline drugs (54)
- Etrasimod (Pfizer) (15)
- Skyrizi (risankizumab; AbbVie) (10)
- Tremfya (guselkumab; Janssen Biotech) (12)
- Ivarmacitinib (Reistone Biopharma) (7)
- Obefazimod (Abivax) (10)
Future treatment trends (21)
- Treatment paradigm for moderate-to-severe UC over the next five years (21)
- Morphic's oral alpha4 beta7 integrin inhibitor could be a first-line UC prospect (13)
Appendix (5)
- KOL details (5)
- KOLs from North America (2)
- KOLs from Europe (2)
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.